Soligenix, Inc. (SNGX)
NASDAQ: SNGX · Real-Time Price · USD
1.370
-0.070 (-4.86%)
At close: Dec 26, 2025, 4:00 PM EST
1.360
-0.010 (-0.73%)
After-hours: Dec 26, 2025, 7:42 PM EST
Soligenix Revenue
In the year 2024, Soligenix had annual revenue of $119.37K, down -85.78%.
Revenue (ttm)
$119.37K
Revenue Growth
-85.78%
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
16
Market Cap
13.82M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 119.37K | -719.99K | -85.78% |
| Dec 31, 2023 | 839.36K | -109.55K | -11.55% |
| Dec 31, 2022 | 948.91K | 124.64K | 15.12% |
| Dec 31, 2021 | 824.27K | -1.54M | -65.07% |
| Dec 31, 2020 | 2.36M | -2.27M | -49.04% |
| Dec 31, 2019 | 4.63M | -611.53K | -11.67% |
| Dec 31, 2018 | 5.24M | -191.02K | -3.52% |
| Dec 31, 2017 | 5.43M | -5.02M | -48.01% |
| Dec 31, 2016 | 10.45M | 1.68M | 19.16% |
| Dec 31, 2015 | 8.77M | 1.73M | 24.50% |
| Dec 31, 2014 | 7.04M | 3.82M | 118.45% |
| Dec 31, 2013 | 3.22M | 79.53K | 2.53% |
| Dec 31, 2012 | 3.14M | -4.52M | -58.96% |
| Dec 31, 2011 | 7.66M | 5.72M | 293.44% |
| Dec 31, 2010 | 1.95M | - | - |
| Dec 31, 2009 | - | - | - |
| Dec 31, 2008 | - | - | - |
| Dec 31, 2007 | 1.26M | -1.06M | -45.61% |
| Dec 31, 2006 | 2.31M | -762.72K | -24.80% |
| Dec 31, 2005 | 3.08M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
SNGX News
- 10 days ago - Positive Clinical Results from Phase 2 Trial of SGX945 for the Treatment of Behçet's Disease Published in Rheumatology (Oxford) - PRNewsWire
- 11 days ago - Soligenix Psoriasis Trial Extension Shows Better Outcomes With New Gel - Benzinga
- 11 days ago - Soligenix Announces Top-line Results of the Phase 2a Study of SGX302 (Synthetic Hypericin) in Patients with Mild-to-Moderate Psoriasis - PRNewsWire
- 25 days ago - Soligenix Inc. (NASDAQ: SNGX) Innovative Platform Provides Novel Treatment for Underserved CTCL Space - GlobeNewsWire
- 5 weeks ago - Soligenix Achieves Enrollment Milestone for Planned Interim Analysis in Confirmatory Phase 3 Clinical Trial of HyBryte™ for the Treatment of Cutaneous T-Cell Lymphoma - PRNewsWire
- 7 weeks ago - Soligenix Announces Recent Accomplishments and Third Quarter 2025 Financial Results - PRNewsWire
- 2 months ago - Soligenix Updates United States Medical Advisory Board for Cutaneous T-Cell Lymphoma - PRNewsWire
- 2 months ago - Soligenix Achieves Important Safety Milestone in its Confirmatory Phase 3 Clinical Trial of HyBryte™ for the Treatment of Cutaneous T-Cell Lymphoma - PRNewsWire